Alzheimer's disease (AD) brain tissue can act as a seed to accelerate aggregation of amyloid-β (Aβ) into plaques in AD transgenic mice. Aβ seeds have been hypothesized to accelerate plaque formation in a prion-like manner of templated seeding and intercellular propagation. However, the structure(s) and location(s) of the Aβ seeds remain unknown. Moreover, in contrast to tau and α-synuclein, an in vitro system with prion-like Aβ has not been reported. Here we treat human APP expressing N2a cells with AD transgenic mouse brain extracts to induce inclusions of Aβ in a subset of cells. We isolate cells with induced Aβ inclusions and using immunocytochemistry, western blot and infrared spectroscopy show that these cells produce oligomeric Aβ over multiple replicative generations. Further, we demonstrate that cell lysates of clones with induced oligomeric Aβ can induce aggregation in previously untreated N2a APP cells. These data strengthen the case that Aβ acts as a prion-like protein, demonstrate that Aβ seeds can be intracellular oligomers and for the first time provide a cellular model of nucleated seeding of Aβ.
Introduction
Protein aggregation is a pathological hallmark of many neurodegenerative disorders such as amyloid-β (Aβ) plaques and tau tangles in Alzheimer's disease (AD) and α-synuclein containing Lewy bodies in Parkinson's disease (PD). However, how these proteins aggregate and spread throughout the brain remain poorly understood. A hypothesis that has been gaining traction the last decade is that these diseaselinked proteins have prion-like properties. Prions are potentially infectious proteins that are capable of misfolding and aggregating (forming amyloid), inducing homologous proteins to misfold and, crucially, can spread and induce misfolding throughout the brain and even between organisms. There is evidence that α-synuclein pathology might spread from host to graft in PD patients who received embryonic stem cell grafts (Kordower et al., 2008; Li et al., 2008) and between cells in culture (Hansen et al., 2011) . Moreover, treatment with fibrillar α-synuclein can seed intracellular inclusions in α-synuclein expressing cells (Luk et al., 2009 ) and intracerebral injection of pathological α-synuclein into α-synuclein expressing mice accelerated formation of Lewy bodies and neurites (Luk et al., 2012) . Tau has also been shown to spread between cells in culture (Holmes et al., 2013) . Intracellular tau inclusions can be formed after addition of fibrillar tau to tau-fragment expressing HEK-293 cells, and injecting these cells into the brains of transgenic tau mice induced tau pathology (Sanders et al., 2014) . For Aβ, studies have shown that intracerebral injections of AD brain material in familial AD (FAD) transgenic mice accelerate amyloid pathology and that it is specifically Aβ that causes this as immuno-depletion of Aβ abolishes seeding activity (Kane et al., 2000; MeyerLuehmann et al., 2006) . Remarkably, as little as a femtogram of PBS soluble AD brain derived Aβ can seed pathology in a FAD mouse (Fritschi et al., 2014) . In contrast, much larger amounts of synthetic Aβ either fail to seed plaques (Meyer-Luehmann et al., 2006) or require nitration or 72 h of agitation of the synthetic Aβ to augment pathology (Kummer et al., 2011; Stöhr et al., 2012 ). It appears that only particular form(s) of Aβ that is (are) present in AD but not normal brains are capable of seeding pathology, albeit in remarkably low quantities. On the basis of these findings it has been argued that Aβ is a prion-like protein (Frost and Diamond, 2010; Jucker and Walker, 2011; Morales et al., 2015) . Understanding where "prion-like" Aβ can form and its structure would then be important for understanding the pathogenesis of AD.
While there is much in vivo work on prion-like Aβ, it has not been shown that one can induce inclusions of Aβ in cultured cells as has been shown for tau and α-synuclein. One reason is practical; Aβ is a low molecular weight metabolite cleaved from within the larger amyloid precursor protein (APP) and it is therefore less feasible to construct a cell line expressing physiologically generated, fluorescently labeled Aβ. This makes it difficult to study Aβ inclusions and transfer in cells. There is also a theoretical reason; as Aβ plaques are extracellular, intracellular Aβ has been viewed as less relevant. However, intraneuronal Aβ42 accumulation is seen before plaques in the brain areas first affected by AD and appears to be among the earliest changes in AD (Gouras et al., 2000) and is associated with synaptic pathology (Takahashi et al., 2002) . Accumulation of intraneuronal Aβ coincides with cognitive symptoms and occurs before plaques in the 3xTg AD mouse (Billings et al., 2005) . Recently it was also reported that FAD mutations in presenilin 2 specifically increase the intracellular pool of Aβ42 (Sannerud et al., 2016) . Furthermore, if conversion of monomeric to aggregated/prion-like Aβ is a stochastic process (Goedert, 2015) , one would expect the biological conversion to happen where concentrations are high as they are in subcellular compartments (Hu et al., 2009) ; the acidic environment of the late endosome/lysosome also favors Aβ aggregation (Burdick et al., 1992) . Thus, if Aβ has prion-like properties, one might expect intracellular prion-like conversion as is the case for prion protein and other prion-like proteins (Aguzzi and Lakkaraju, 2016; Luk et al., 2009; Sanders et al., 2014) .
In this study we induce human APP expressing N2a neuroblastoma cell lines to stably form intracellular inclusions of Aβ by treating them with AD transgenic mouse brain extracts. We characterize these cell lines biochemically and with infrared (IR) absorbance spectroscopy and conclude that the inclusions are oligomers. We show that lysates of the inclusion bearing cells, a purely cellular source of Aβ, can be used to induce naive APP-expressing cell lines to also form inclusions. In summary, we provide a cellular model of seeded nucleation of Aβ, where the inclusion forming Aβ can be propagated both vertically (the phenotype is stable over time) and horizontally (naive cells can be infected). These data are consistent with prion-like conversion of intracellular Aβ.
Materials and methods

Preparation of mouse brain material
The forebrains of 21-month-old APP/PS1 (The Jackson laboratory, B6C3-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax), Tg19959 harboring the Swedish and London mutations in APP (Li et al., 2004) or wild type (WT) mice were collected and immediately frozen on dry ice and stored at −80°C. The forebrains were homogenized in 10% weight/volume sterile PBS, sonicated 3 times for 5 s at 80% amplitude with a Branson SLPe model 4C15 sonifier and centrifuged at 3000g for 5 min. The resulting supernatant was sonicated 3 times for 20 s each at 80% amplitude as described in Langer et al., 2011 (Langer et al., 2011 . The supernatant was then aliquoted and kept at −80°C until use.
Cell culture
N2a cells were grown in media containing 47% high glucose DMEM, 47% Optimem, 5% FBS and 1% penicillin/streptomycin at 37°C in a humid 5% CO 2 incubator. Single cell cloning was done via serial dilution in 96 well plates.
Cell pellet collection
Cells were washed twice on ice with ice-cold PBS and collected with a cell scraper. Cells were then pelleted at 10,600g for 2 min at 4°C, snap-frozen in liquid nitrogen and stored at −80°C.
Treatment with brain supernatant
N2a cells expressing human APP with the Swedish mutation (APPswe) were passaged and the following day treated with brain supernatant at a concentration of 0.5% from either aged APP/PS1 or WT mice in Optimem with 1% penicillin/streptomycin and 0.5% FBS; low serum media was used to inhibit cell growth. The supernatant was kept on the cells for 4 days at a time and then passaged and treated again or single cell cloned to isolate cells with aggregates.
Immunocytochemistry
Cells were grown on glass coverslips (VWR 12 mm microscope cover glasses). Cells were washed 3 times on ice with ice cold PBS, fixed with cold 4% PFA in PBS for 15 min at room temperature (RT) and then washed 3 times with PBS at RT. Blocking, to reduce unspecific antibody binding, was done with 2% NGS, 1% BSA and 0.1% saponin in PBS for 1 h. Cells were stained with primary Aβ/C99 N-terminus-specific antibody 82E1 (IBL) at 1:200 and fibrillar oligomer-specific Aβ antibody OC (Millipore) 1:1000 in PBS 2% NGS overnight at 4°C. Cells were then washed with PBS-T for 5 min, 15 min and 15 min. Then incubated with secondary antibodies at 1:500; AF488 anti-mouse and Cy3 anti-rabbit (Jackson ImmunoResearch) for 1 h at RT in the dark. Cells were again washed with PBS-T 3 times for 5 min each and during the second wash 0.1% DAPI was added. Coverslips were then mounted on glass slides with slow fade gold anti-fade reagent (Life Technologies) dried in the dark overnight and then sealed with Covergrip Coverslips Sealant (Biotum).
Confocal microscopy
Images were obtained using a Leica TCS SP8 confocal microscope (Leica Microsystems) equipped with Diode 405/405 nm and Argon (405, 488, 552, 638 nm) lasers with an HP PL APO 63x/NA1.2 water immersion objective. Autoquant (MediaCybernetics) was used for image deconvolution. Two-dimensional images obtained by confocal microscopy were reconstructed using Imaris (Bitplane).
Blue native (BN) PAGE
N2a cell pellets were triturated and incubated on ice for 30 min in a buffer solution of 20 mM Tris, 50 mM NaCl, 1% triton X pH adjusted to 7.4 with HCl and with 1:100 protease inhibitor cocktail (Thermo Fisher Scientific). The cells were then centrifuged at 10,600g at 4°C for 20 min, mixed with NativePAGE sample buffer 4× (Thermo Fisher Scientific) and loaded onto 3-12 or 4-16% Bis Tris protein gels (Thermo Fisher Scientific). Native-Mark unstained protein standards (Invitrogen) were used as molecular weight markers with the addition of a 14 kDa marker (Sigma-Aldrich). Before protein transfer, the gels were washed with running buffer with 0.1% added SDS (Sigma) for 10 min. Transfers for all protein electrophoresis gels were done onto polyvinylidene difluoride (PVDF) membranes (iBlotR, NovexR, Life Technologies). Membranes were then boiled in PBS for 5 min and blocked in 5% skim milk in PBS-T for 30 min at RT. Primary antibody incubation was done at 4°C overnight in 5% skim milk PBS-T; for BN-PAGE, antibody 82E1 was used at 1:700. The membranes were then washed 4 times for 20 min each in PBS-T and incubated with secondary HRP antibody 1:2000 for 1 h in 5% skim milk in PBS-T at RT. The membranes were then washed 3 times for 15 min each in PBS-T and developed with Clarity western ECL blotting substrate (Bio-Rad).
Dot blot
Cell Samples were prepared as for BN-PAGE. 1 μl of sample was put on a nitrocellulose membrane and allowed to dry and then washed with PBS-T for 15 min 3 times and blocked for 30 min in 5% skim milk PBS-T. Primary antibody incubation was done at 4°C overnight in 5% skim milk PBS-T and A11 or OC was used at a concentration of 1:5000. After primary incubation the procedure is identical to that of BN-PAGE.
Semi denaturing detergent (SDD) PAGE
The cells were either lysed as for BN PAGE or as 20% wt/vol T.T. Olsson et al. Neurobiology of Disease 113 (2018) 1-10 sonicated (3 times for 5 s at 80% amplitude) PBS extracts. Cell samples were mixed with Novex Tricine SDS Sample Buffer (2×) (Thermo Fisher Scientific) to a final SDS concentration of 4 or 2%. Cell samples were incubated with the sample buffer for 10 min at RT and then loaded onto 10-20% Tricine Protein Gels (Novex 10-20% Tricine Protein Gels, 1.0 mm, 10-well). SeeBlue Plus2 Pre-stained Protein Standard (Thermo Fisher Scientific) was used as a protein standard.
Proteinase K treatment
Samples were incubated for 1 h at 37°C with 50 μg/ml proteinase K solution (Thermo Fisher Scientific) after which protease inhibitor cocktail 1:100 (Thermo Fisher Scientific) was added and the samples were then immediately analyzed.
SDS PAGE
Sample cells were lysed in 6% SDS and 1% β-mercaptoethanol in PBS, sonicated twice for 20 s at 20% amplitude (Branson SLPe model 4C15 sonifier), heated to 95°C for 5 min and centrifuged at 10,600g for 10 min. Supernatants were mixed with SDS Sample Buffer (2×) (Thermo Fisher Scientific) with 0.8% β-mercaptoethanol, heated to 95°C for 5 min, briefly centrifuged and then loaded onto 10-20% Tricine Protein Gels with SeeBlue Plus2 Pre-stained Protein Standard (Thermo Fisher Scientific) used as a protein standard ladder. Densitometric quantifications were done with imageJ.
Fourier transform infrared (FTIR) spectroscopy
Spectra were recorded on a Hyperion 3000 IR microscope (Bruker Scientific Instruments, Billerica, MA, USA) coupled to a Tensor 27, which was used as the IR light source with 15× IR objective and MCT (mercury cadmium telluride) detector. The measuring range was 900-4000 cm −1 , the spectra collection was done in transmission mode at 4 cm −1 resolution from 250 co-added scans. Background spectra were collected from a clean area of the same CaF 2 window. All measurements were made at RT. Samples were prepared by spreading 1 μl of cell pellet on the CaF 2 1 mm window surface and rapidly dried under nitrogen flow. For reproducibility, FTIR spectra were taken from different areas of the cell pellet deposited on CaF 2 . Analysis of FTIR spectra was performed using OPUS software (Bruker). After atmospheric compensation, spectra exhibiting strong Mie scattering were eliminated. For all spectra a linear baseline correction was applied from 1400 cm −1 to 2000 cm −1 . Derivation of the spectra to the second order was used to increase the number of discriminative features to eliminate the baseline contribution. Derivation of the spectra was achieved using a Savitsky−Golay algorithm with a six-point filter and a polynomial order of three. In FTIR spectroscopy, β-sheet structures can be distinguished based on the analysis of the amide I (1700-1600 cm
) α-helix and unordered structures can each be assigned to bands at 1656 cm −1 and to 1640 cm
, respectively. The level of β-aggregation of proteins in the cells was studied by calculating the peak intensity ratio between 1620 and 1640 cm −1 corresponding to β-sheet structures and the maximum corresponding mainly to α-helical content at 1656 cm −1
. An increase in the 1620-1640 cm −1 component was considered a signature of β-sheet structures (Ami et al., 2016) . Since β-sheet structures have two typical components in the amide I region: the major component has an average wavenumber located at about 1630 cm −1 , and a minor component, at 1695 cm −1 ; the 1695/ 1630 intensity ratio was used to study the percentage of antiparallel arrangements of the β-strands in the β-sheets (Cerf et al., 2009 ).
Antibodies used
Anti-β-Actin, Clone AC-74 (Sigma-Aldrich), 82E1 (IBL), 6E10 (Signet), A11 (Millipore) and OC (Millipore).
Statistical methods
One-way analysis of variance was used for all p-value calculations followed by Bonferroni correction for multiple comparisons; *, **, *** and **** are p ≤ 0.05, 0.01, 0.001 and 0.0001 respectively. ShapiroWilk normality test (alpha = 0.05) was used to assess distribution and no significant departure from normality was found for any data sets. The individual data points are shown in the bar-plots. All statistical calculations were done with Graphpad Prism 7.
Results
AD transgenic mouse brain extracts seed Aβ inclusions in APP expressing N2a cells
To test whether intracellular seeded nucleation and prion-like conversion of Aβ can occur in cells, we aimed to seed stable Aβ inclusions in an APP expressing cell line. To this end, we treated N2a cells expressing human APP carrying the Swedish mutation (APPswe) with the PBS dispersible fraction of homogenized brains from 21-month old APP/PS1 mutant transgenic or wild type (WT) mice. APPswe cells were incubated with brain extract for 4 days and then passaged and treated with brain extract two more times for a total of 12 days of treatment (Fig. 1A) . Analogously to seeded nucleation of misfolded tau in cells (Sanders et al., 2014) , we expected only a minority of cells to undergo prion-like conversion of Aβ; to isolate these we performed single cell cloning. Single cell clones were then labeled with antibodies 82E1 against the N-terminus of Aβ/C99 (99 amino acid carboxyl-terminal APP fragment) and OC against oligomers/fibrils (Kayed et al., 2007) . 7 out of 22 single cell clones that had earlier been treated with APP/PS1 transgenic mouse brain extract showed puncta of antibody 82E1 colocalizing with antibody OC, while none of the 18 WT brain treated clones had such labeling (Fig. 1B and C) . Western blot indicates that the levels of cellular C99 are very low compared to Aβ in the treated cells ( Supplementary Fig. 1 ) supporting that antibody 82E1 is mainly detecting Aβ. Thus, the co-localization of antibodies 82E1 and OC indicate the presence of oligomeric and/or fibrillar Aβ in the AD transgenic brain extract treated clones. Next, we repeated the treatment with APP/ PS1 brain extract on naive APPswe cells but now treated the cells only 2 times, for a total of 8 days of treatment. This only yielded 1 out of 20 single cell clones with 82E1 and OC positive inclusions, indicating that fewer cells develop inclusions with shorter duration of treatment with APP/PS1 brain extract. We additionally tested the seeding capacity of aged brain extract from a different transgenic mouse, 31-month old Tg19959, and obtained 3 of 19 clones with inclusions ( Supplementary  Fig. 2D and E). To show vertical stability (over time and passage number) of the inclusions, we labeled them again after > 10 passages and 6 months of storage at −80°C. Remarkably, the FAD brain treated cells retained their inclusions (Fig. 1D) . We therefore conclude that we seeded stable oligomeric and/or fibrillar inclusions of Aβ in an APPexpressing cell line by treatment with AD transgenic mouse brain, which is consistent with prion-like conversion of intracellular Aβ. These inclusion-bearing cells that have been treated with transgenic brain lysate will be referred to as "prion-like clones" and those treated with WT brain lysate as "WT-clones".
Intracellular Aβ from prion-like clones seeds Aβ aggregation in N2a APPswe cells
To determine whether the intracellular Aβ of the prion-like cells is capable of seeded nucleation, we treated naive APPswe cells with prionlike cells or WT-clone cells. We used the same protocol as with homogenized brain tissue but replaced brain extracts with the PBS dispersible fraction of cells and treated the naive cells for a longer time period, 7 treatments, for a total of 28 days. We hypothesized that the seeding activity of the prion-like cells would be lower than that of brain, hence Further analysis of the inclusionbearing single cell clones by confocal microscopy showed antibody OC and 82E1 positive puncta that were similar to those observed in the first prion-like clones obtained after treatment with brain extracts (Fig. 1E and Supplementary Fig. 2 ). Since the daughter clones of prion-like clone 3 (prion-like clone 3a) had the strongest labeling, we used this cell clone for further analysis. Thus, prion-like cell extracts, analogous to the APP/PS1 brain extracts, can seed Aβ aggregates in an APP expressing cell line and appear to do so with comparable efficiency, consistent with horizontal stability of the Aβ inclusions.
Prion-like clones contain 250-670 kDa oligomeric Aβ
Antibody OC and 82E1 positive inclusions indicated the presence of oligomeric and/or fibrillar Aβ in the prion-like clones. To show this with another method and to estimate their size and thereby discriminate between oligomers and fibrils, we performed Blue Native Polyacrylamide Gel Electrophoresis (BN-PAGE). BN-PAGE allows analysis of protein complexes in their folded and potentially aggregated state, where mobility in the electrophoresis gel depends both on the size and charge of protein complexes. Interestingly, BN-PAGE revealed aggregates in the 250-670 kDa range in all prion-like clones studied, particularly in prion-like clone 3; prion-like clone 2 also had robust labeling while it was a bit weaker in clones 1 and 4 ( Fig. 2A and B) . In contrast, WT-clone cells barely showed any labeling on BN-PAGE. BN-PAGE provided further evidence for the vertical stability of oligomer formation, as it appeared similar after numerous passages and storage at −80°C ( Fig. 2A and B) . The horizontal stability of oligomer formation was also evident as both prion-like clone 3 and its daughter clone prion-like 3a harbor oligomers of similar size (Fig. 2B) .
To further study the Aβ oligomers we performed dot blots with the conformation dependent antibodies A11 and OC. This revealed increased levels of OC in the prion-like clones and unchanged levels of A11 (Fig. 2C) . The size of the Aβ complexes on BN-PAGE, together with the OC labeling both on dot blot and immunofluorescence, suggests that the intracellular Aβ-inclusions are fibrillar oligomers (Glabe, 2008) .
3.4. The prion-like clones display greater resistance to SDS but are sensitive to proteinase K Amyloid and prions are more stable than other protein complexes and therefore only partially broken up with SDS treatment (Bagriantsev et al., 2006) . It has also been suggested that SDS-stable low-n oligomers of Aβ are the building blocks of amyloid deposits, as well as early mediators of neuronal dysfunction (Walsh and Selkoe, 2007) . We therefore hypothesized that the Aβ of prion-like clones would have greater SDS resistance and more low n-oligomers compared to that of WT-clones. Semi-denaturing detergent agarose gel electrophoresis (SDD-AGE) is used to break up aggregates of amyloid and prion protein into SDS stable components (Kryndushkin et al., 2003) . However, since the pores in agarose gels are too large for low-n oligomers of Aβ, we modified the SDD-AGE protocol to use polyacrylamide rather than agarose and refer to this as SDD-PAGE. In contrast to SDS-PAGE, in SDD-PAGE cells are lysed without SDS or β-mercaptoethanol (a reducer of disulfide bonds), boiling is avoided and sample buffer with lower SDS concentration is used. SDD-PAGE on WT-clone cells lysed with sonication in PBS yielded only one non-monomeric band at around 50 kDa, while in the prion-like clones several bands, as well as a high molecular weight (HMW) smear, were evident, indicating greater stability of their Aβ aggregates (Fig. 2D) . Moreover, SDD-PAGE of the prion-like clones lysed with Triton-X showed higher levels of Aβ, including the presence of oligomers of Aβ up to 50 kDa, as well as a HMW smear, that were not present in WT-clone cells; as with BN-PAGE, this was particularly apparent for prion-like clone 3 (Fig. 2E) .
A cardinal feature of prion disease is resistance to proteinase K (PK) (Prusiner, 1998) . Pertaining to AD, seeding Aβ from mouse brain extracts was reported to be partly PK-resistant, however, ultracentrifuged (100,000g) brain extracts, containing only soluble Aβ, was PK-sensitive (Langer et al., 2011) . We investigated the PK-sensitivity of the prionlike clones with native PAGE and dot blot and found the Aβ to be PKsensitive ( Supplementary Fig. 4 ). The Aβ of the prion-like clones is soluble and the PK-sensitivity is thus consistent with prior results reported in brain tissue (Langer et al., 2011) .
The prion-like clones have higher levels of Aβ, C99 and APP
Studies have shown that the intracellular accumulation of Aβ affects APP processing and degradation (Davis-Salinas et al., 1995; Yang et al., 1995 Yang et al., , 1999 . Thus, we wanted to study the levels of APP and its metabolites in our clones. Since the Aβ in the prion-like clones had greater resistance to SDS degradation, we expected the levels of Aβ to be higher in them due to potentially decreased degradation. Indeed, SDS-PAGE showed higher levels of both intra-and extra-cellular Aβ in the prionlike clones (Fig. 3A and B) . The Aβ levels were highest in the prion-like clone 3, as would be expected from the BN-PAGE and SDD-PAGE data. Increased Aβ could be caused by more APP, increased amyloidogenic β-cleavage of APP or decreased degradation. C99 was also significantly increased in the prion-like clones (Fig. 3C) . It has been reported that addition, and subsequent intracellular accumulation and aggregation of Aβ42, led to increased β-cleavage of APP into Aβ (Yang et al., 1995 (Yang et al., , 1999 , supporting that increased β-cleavage is causing the increase of C99 and Aβ in the prion-like clones; though, increased β-cleavage and decreased degradation are not mutually exclusive. Full-length APP was also significantly increased in the prion-like clones (Fig. 3D) , and again, Fig. 1 . Treatment with FAD transgenic but not wild-type mouse brain extract produces inclusions in APP expressing N2a cells that are stably propagated. A: Outline of treatment: The homogenized forebrain of an aged APP/PS1 transgenic mouse is added to the media of N2a cells expressing APP with the Swedish mutation (APPswe); this treatment is then repeated 2 more times after passage of the APPswe cells. The APP/PS1 brain treated cells are then single cell cloned; single cell colonies are transferred to a 24-well plate and labeled with antibodies to detect Aβ inclusions. B: Confocal image of one of the clones with inclusions after treatment with mouse FAD brain homogenate (prion-like clone 4). Note the inclusions positive for antibodies 82E1 and OC, which indicate oligomeric and/or fibrillar Aβ. C: N2a APPswe cells that have been treated with aged WT mouse brain and then single cell cloned do not show such inclusions. D: After 11 passages and 6 months storage at −80°C prion-like clone 3 retains its inclusions. E: Prion-like clone 3a; N2a APPswe cells that were treated with lysates from prion-like clone 3 cells rather than brain homogenate develop the same inclusion as prion-like clone 3. The scale bars are 20 μm. F: Table summarizing the different treatments of APP-swe cells including number of times they were treated, the total duration of treatment and the number of single cell clones with antibody 82E1 (Aβ) co-localizing with antibody OC. Fig. 1. (continued) T.T. Olsson et al. Neurobiology of Disease 113 (2018) 1-10 increased APP due to accumulation of Aβ has been reported (DavisSalinas et al., 1995; Yang et al., 1995) . More APP should also raise the levels of Aβ. Levels of secreted soluble APPα (sAPPα, a product of nonamyloidogenic α-cleavage of APP) in media were however unchanged (Fig. 3E) , which is also consistent with previous reports (Davis-Salinas et al., 1995; Yang et al., 1995) . The ratio of sAPPα:APP is therefore decreased in the prion-like clones compared to WT-clone cells, suggesting lower non-amyloidogenic α-cleavage of APP in prion-like clones.
3.6. Prion-like clones have increased unordered structure and anti-parallel β-sheet formation consistent with Aβ oligomers
To further study the structures of the induced Aβ oligomers detected by BN-PAGE, dot blot and immunofluorescence, we used non-destructive Fourier transform infrared (FTIR) micro-spectroscopy imaging. FTIR has mostly been used on pure protein preparations but can also be used for cells and tissue (Ami et al., 2016; Klementieva et al., 2017) , though some caution is warranted when comparing cell data with those from pure protein preparations. 1 μl of cell pellet was spread onto CaF 2 sample support surfaces and dried under nitrogen flow. FTIR measurements were done on several different locations of the dried cell pellet (Supplementary Fig. 5 ). We detected a significant increase in unordered structures (the ratio between the absorbance at 1639 cm −1 and 1656 cm −1 ) in all prion-like clones ( Fig. 4A and B) . Importantly, the amount of unordered structures remains elevated after several passages. Oligomers of Aβ have been suggested to have more unordered structures than fibrillar Aβ (Wu et al., 2010) . Surprisingly, the level of total β-sheet content (the ratio between the absorbance at 1627 cm
and 1656 cm −1 ) remained at a similar level between WT-clones and prion-like clones (Fig. 4A) , while total β-sheet content in WT-clone cells (that have APP with the FAD Swedish mutation) was significantly increased (p < 0.001) compared to N2a cells expressing human nonmutated APP. This suggests that the total content of fibrillar structures is not higher in prion-like clones than in WT-clones. Interestingly, antiparallel β-sheet content (the ratio between the absorbance at 1693 cm −1 and 1627 cm −1
) was significantly increased in all prion-like clones (Fig. 4C) . Antiparallel structures have been linked to A11 positive oligomers of Aβ, though OC-reactivity was not investigated in that study (Cerf et al., 2009) ; it has also been shown that both A11 and OCpositive oligomers exhibit more antiparallel structures than fibrils (Breydo et al., 2016) . In summary our FTIR results show a clear difference in the secondary protein structure of the prion-like clones, which is consistent with an increase of oligomeric but not fibrillar Aβ.
Discussion
A major question in the field is which forms of Aβ have seeding capacity ). Here we provide data suggesting that intracellular fibrillar oligomers of Aβ can be a seeding unit. We Both gels in E are the same blot with the right blot exposed longer. Uncropped blots can be seen in Supplementary  Fig. 3. T.T. Olsson et al. Neurobiology of Disease 113 (2018) 1-10 demonstrate that seeded nucleation of Aβ can be induced intracellularly in an APP producing cell line by treatment with mouse FAD brain extract. Native PAGE, labeling with conformation dependent antibodies and infrared spectroscopy support that the inclusions were oligomeric, and in the terminology introduced by Kayed et al., "fibrillar oligomers" (Kayed et al., 2007) . Furthermore, SDS treatment revealed SDS-resistant low n-oligomers, indicating aggregates reminiscent of amyloid and prion aggregates (Bagriantsev et al., 2006) . Moreover, cells with induced Aβ aggregates could seed Aβ aggregation in naive APP-expressing cells, thus demonstrating seeded nucleation with a purely intracellular source of Aβ. Remarkably, native PAGE and infrared spectroscopy indicated that the Aβ oligomers from the parent clone were similar to those from the daughter clone. These data are consistent with formation of fibrillar oligomeric strains of intracellular prion-like Aβ that can be transmitted both vertically and horizontally. Numerous studies underscore an early role of intraneuronal Aβ in AD pathogenesis (Billings et al., 2005; Gouras et al., 2010; Takahashi et al., 2002) . According to the prion-like hypothesis this stochastic formation of prion-like Aβ would be one of the earliest steps in AD. Though most Aβ is normally secreted, the probability of stochastic conversion of physiological Aβ to prion-like/seeding Aβ should depend on concentration (Goedert, 2015) and the highest concentrations of soluble Aβ are found in intracellular vesicles (Hu et al., 2009 ). Furthermore, it has been reported, and we also observe, that intracellular accumulation and aggregation of added synthetic Aβ42 increased cleavage of APP into Aβ and increases levels of APP (Davis-Salinas et al., 1995; Yang et al., 1995 Yang et al., , 1999 , potentially creating a positive feedback loop of increased intracellular Aβ aggregation and production. Yang et al. did not investigate whether this intracellular Aβ aggregation persisted over replicative generations. It is possible that they achieved intracellular prion-like conversion with synthetic Aβ, albeit with the extremely high concentration of 25 μM Aβ42, whereas our treatment of cells with brain extract contains approximately 20 nM Aβ and with prion-like cell extract about 2 nM. Considering the results of Yang et al., the fact that in vivo seeding of Aβ can be achieved with synthetic Aβ (Kummer et al., 2011; Stöhr et al., 2012) and that α-synuclein and tau seeding can be done with synthetic fibrils, it's likely that in vitro prionlike intracellular seeding can be accomplished with some specific aggregation states and concentrations of synthetic Aβ.
Ultracentrifugation of AD brain was reported to remove > 99.95% of Aβ, while only reducing seeding capacity by 70% (Langer et al., 2011) . This suggests that the most potent seeding Aβ species are relatively small soluble oligomers rather than larger insoluble fibrils. It was also noted that this potently seeding soluble Aβ is destroyed by PKdigestion (Langer et al., 2011) ; the Aβ of our prion-like clones is also PK-sensitive. However, seeding Aβ appears not to be present in CSF, as intracerebral injection of CSF, a cell-free physiological source of soluble Aβ, from aged AD patients failed to seed aggregation (Fritschi et al., 2014) . A 2016 study showed that some of the seeding Aβ from a homogenized mouse brain with plaques was associated with mitochondrial membranes and was non-fibrillar (Marzesco et al., 2016) ; this is consistent with intracellular seeding Aβ in the brain, though after homogenization of plaque-ridden brain an extra or intra-cellular origin of a given pool of Aβ is difficult to ascertain. Theoretically it also seems There are also significantly higher levels of full-length APP in all prion-like clones tested. E: No significant difference is detected in soluble APPα between a WT-clone and the prion-like clones. F: Representative images of the SDS-PAGE western blots used for densitometric quantification with imageJ. Note that the C99 blot has been cropped to show samples in duplicate, it was originally a triplicate. Antibody 82E1 was used to blot Aβ and C99; antibody 6E10 was used for fulllength APP and sAPPα. All values are normalized to actin. Tests for statistical significance were done between the WT-clone and the prion-like clones (*, **, *** and **** are p ≤ 0.05, 0.01, 0.001 and 0.0001 respectively).
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(caption on next page) T.T. Olsson et al. Neurobiology of Disease 113 (2018) 1-10 plausible that oligomers can be more biologically active as seeds due to their higher surface area and higher molarity at equivalent weights compared to fibrils. Indeed, it has been observed that the prions in Creutzfeldt-Jakob disease with the greatest prion-like conversion potency are smaller protease sensitive oligomers (Kim et al., 2012) . In humans it has been noted that the soluble pool of Aβ in AD brain correlates with cognitive decline (McLean et al., 1999; Wang et al., 1999) . It has furthermore been observed that it is specifically the fibrillar (OC positive) oligomer load that correlates with cognitive decline and that they are absent in CSF (Tomic et al., 2009) . Thus, it is noteworthy that the intracellular prion-like Aβ we report also seems to consist of fibrillar oligomers. However, while immunofluorescence and dot blot show more OC labeling in prion-like cells, the FTIR data is more ambiguous. The increased anti-parallel structures we observe are associated with Aβ oligomers, but more so with A11 than OC (Cerf et al., 2009; Wu et al., 2010) ; though those studies were based on pure protein preparations, not cells.
Conclusions
We establish, for the first time, that intracellular inclusions of Aβ can be seeded and stably maintained in an APP expressing cell line. These inclusions can propagate both vertically (stable phenotype over time) and horizontally (inclusion can be induced in a naive APP-expressing cell line). The seeding Aβ inclusions are oligomers, likely fibrillar, of Aβ with low-n oligomers resistant to SDS. There is an extensive literature indicating an early and important role of intraneuronal Aβ and of oligomeric Aβ in the pathogenesis of AD, and our results support a novel connection between intracellular Aβ, soluble fibrillar oligomers of Aβ and prion-like Aβ.
